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Purpose: To assess the safety and efﬁcacy of different doses of RTH258 applied as single intravitreal
administration compared with ranibizumab 0.5 mg in patients with neovascular age-related macular degeneration
(AMD).
Design: Six-month, phase 1/2, prospective, multicenter, double-masked, randomized, ascending single-
dose, active-controlled, parallel-group study.
Participants: A total of 194 treatment-naive patients, aged 50 years, with primary subfoveal choroidal
neovascularization secondary to AMD.
Methods: Patients received a single intravitreal injection of RTH258 0.5 mg (n ¼ 11), 3.0 mg (n ¼ 31), 4.5 mg
(n ¼ 47), or 6.0 mg (n ¼ 44), or ranibizumab 0.5 mg (n ¼ 61).
Main Outcome Measures: The primary efﬁcacy end point was the change from baseline to month 1 in
central subﬁeld thickness (CSFT) measured by spectral-domain optical coherence tomography. The secondary
efﬁcacy end point was the duration of treatment effect measured as time from the initial injection to receipt of
post-baseline therapy (PBT) guided by protocol-deﬁned criteria. Adverse events (AEs) were recorded throughout
the study.
Results: RTH258 demonstrated noninferiority compared with ranibizumab in mean change in CSFT from
baseline to month 1 for the 4.5- and 6.0-mg dose groups (margin: 40 mm, 1-sided alpha 0.05). The difference in
CSFT change at month 1 comparison with ranibizumab was 22.86 mm (90% conﬁdence interval [CI], 9.28 to
54.99) and 19.40 mm (95% CI, 9.00 to 47.80) for RTH258 4.5 and 6 mg, respectively. The median time to PBT
after baseline therapy was 60 and 75 days for patients in the RTH258 4.5- and 6.0-mg groups, respectively,
compared with 45 days for ranibizumab. Changes in best-corrected visual acuity with RTH258 were compa-
rable to those observed with ranibizumab. The most frequent AEs reported for the RTH258 groups were
conjunctival hemorrhage, eye pain, and conjunctival hyperemia; the majority of these events were mild in
intensity.
Conclusions: This ﬁrst-in-human study of RTH258 demonstrated noninferiority in the change in CSFT at 1
month for the 4.5- and 6.0-mg doses compared with ranibizumab and an increase of 30 days in the median time
to PBT for the 6.0-mg dose. There were no unexpected safety concerns, and the results support the continued
development of RTH258 for the treatment of neovascular AMD. Ophthalmology 2016;123:1080-1089 ª 2016 by
the American Academy of Ophthalmology. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
Supplemental material is available at www.aaojournal.org.Macular diseases, notably age-related macular degeneration
(AMD), are leading causes of irreversible blindness and
visual impairment. The 2010 global population statistical
data indicate that 1 in 15 blind people and 1 in 32 visually
impaired people had macular disease.1 In addition, the rate
of blindness due to macular diseases increased by 36%
from 1990 to 2010.11080  2016 by the American Academy of Ophthalmology
This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/). Published by Elsevier IncAntievascular endothelial growth factor (VEGF) thera-
pies and novel imaging techniques, including spectral-
domain optical coherence tomography (SD OCT), have
contributed to remarkable improvements in early diagnosis,
monitoring, and functional outcomes for patients with neo-
vascular AMD2 leading to decreasing or at least stable
prevalence of blindness and visual impairment associated.
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VEGF therapies delivered via intravitreal injection include
ranibizumab and aﬂibercept, as well as off-label bev-
acizumab,5 and national and international guidelines
recommend these anti-VEGF agents as ﬁrst-line therapy
for the treatment of neovascular AMD.5,6 Research is
ongoing regarding other molecular targets in the AMD
disease pathway, including platelet-derived growth factor,
mammalian target of rapamycin, several complement com-
ponents, and combination therapies to improve the treatment
of wet and dry AMD.7
Although anti-VEGF therapies have resulted in improved
patient outcomes, there are limitations associated with these
treatments. Anti-VEGF therapies require frequent clinical
assessment to monitor patient response to treatment and, in
some cases, monthly or bimonthly intravitreal injections.2,7
The burden associated with frequent clinic visits or intra-
vitreal injections for patients, caregivers, and physicians is
signiﬁcant and may lead to suboptimal outcomes because of
adherence problems and underdosing.2 LUMINOUS, an
ongoing 5-year prospective, multinational, observational
study designed to evaluate the outcomes of treatment with
ranibizumab 0.5 mg in routine clinical practice, showed that
patients with newly diagnosed neovascular AMD have an
average of 7.5 visits and 4.7 injections in the ﬁrst year of
therapy, resulting in a gain of 4.4 letters. Over 2 years, the
average number of visits was 13.6 with 8.7 injections and a
gain of 2 letters.8 Thus, there is a logistical disconnect
between the realities of community practice and the strict
monthly-visit regimen of well-known clinical trial sched-
ules.9e12 The AURA (A retrospective noninterventional
study to assess the effectiveness of existing Anti-vascUlar
endothelial growth factor [anti-VEGF] treatment Regimens
in patients with wet Age-related macular degeneration)
study, a retrospective analysis of 2227 real-world ranibizu-
mab-treated patients with wet AMD who were followed for
2 years, reported a good initial response to therapy, with
improved visual acuity over the ﬁrst 120 days.13 However,
the average gains in visual acuity were not maintained
over the 2-year follow-up.13 Intravitreal injections declined
from a mean of 5.0 injections in the ﬁrst year to 2.2
injections in the second year. There was also a decline in
the number of visits to the treating ophthalmologist over
the same time period.13 Alternative treatments or long-
acting drug delivery systems would be required to offset
the compromise between treatment burden and visual out-
comes by increasing the drug efﬁcacy and durability of
treatment response.7,14
RTH258 (formerly ESBA1008) is a humanized single-
chain antibody fragment that inhibits all isoforms of
VEGF-A. It is the smallest anti-VEGF inhibitor tested in
humans with a molecular weight of only 26 kDa compared
with 48 kDa for ranibizumab or 115 kDa for aﬂibercept.15
Because of its high stability and solubility, it is possible to
concentrate RTH258 up to 120 mg/ml, allowing the
administration of 6 mg in a single 50-ml intravitreal
injection.15 This enables the delivery of a much higher
molar dose in the same volume as the current VEGF
inhibitors in clinical use,15,16 potentially supporting an
early initiation and a prolonged duration of treatment effect.Furthermore, animal studies have shown that the small size
of RTH258 leads to a fast systemic clearance and a 4-fold
lower systemic exposure15,16 compared with anti-VEGF
agents like ranibizumab and bevacizumab, potentially
reducing the risk of systemic side effects. The smaller size
also may allow for better ocular tissue penetration.16 The
tolerability of high doses of RTH258 in animals, the high
afﬁnity to VEGF, and the lower molecular weight suggest
that RTH258 may be an effective ocular anti-VEGF ther-
apy in humans, with extended duration of efﬁcacy.
The objective of this ﬁrst-in-human study was to assess
the safety, tolerability, and effect of treatment on ocular
outcomes after a single intravitreal administration of 1 of 4
dose levels of RTH258 compared with ranibizumab 0.5 mg
in patients with neovascular AMD.Methods
Study Design
This phase 1/2, 6-month, prospective, multicenter, double-masked,
randomized, ascending single-dose, active-controlled, parallel-
group study compared the safety and efﬁcacy of a single intra-
vitreal injection of RTH258 (ascending doses) or ranibizumab as
therapy for treatment-naive patients with neovascular AMD. The
study protocol was approved by all institutional review boards and
complied with the ethical standards deﬁned by the Declaration of
Helsinki and Good Clinical Practice. All patients provided written
informed consent before participating in the study (Clinical-
Trials.gov identiﬁer, NCT01304693).
The study was conducted in 2 phases: (1) a dose escalation
phase of RTH258 to the maximum feasible dose (MFD) for
intravitreal injection (MFD ¼ 6.0 mg RTH258) and (2) an MFD
expansion phase. In the dose escalation phase, patients were
randomized 5:2 to receive RTH258 (0.5, 3.0, or 4.5 mg) or
ranibizumab 0.5 mg. Each dose level cohort was reviewed by a
safety committee before the next ascending dose level cohort was
treated and evaluated. Details regarding the safety review deci-
sion points for the ascending doses and the stopping criteria for
the study are reported in the Appendix (available at
www.aaojournal.org). Within each dose level cohort, the ﬁrst 4
patients enrolled and treated with a single dose were
sequentially assessed with a waiting period of 24 hours
between patients to allow sufﬁcient time for safety review for
each patient before approving injection of the next patient.
After the ﬁrst 4 patients in a given dosing cohort received
treatment and were reviewed for safety, the remaining patients
in the cohort were treated in parallel.
The MFD expansion phase of the study consisted of 2 parts. In
the ﬁrst part, patients were randomized 1:1 to RTH258 4.5 mg or
ranibizumab 0.5 mg. In the second part, patients were enrolled and
randomized 5:30:35:9 to RTH258 0.5-, 3.0-, or 6.0-mg doses, or
ranibizumab 0.5 mg. The randomization schedule was determined
in part by additional data requirements for separate pharmacoki-
netic/pharmacodynamic studies related to RTH258.
All randomized patients were evaluated for safety and efﬁcacy
over 13 study visits, including screening, day of treatment, and 11
post-treatment follow-up visits (day 1, weeks 1 and 2, and months
1, 1.5, 2, 2.5, 3, 4, 5, and 6). Eligible patients were randomized
using an interactive web response system to receive a single
intravitreal injection of their assigned study drug in the study eye
on day 0. Details regarding the randomization process are provided
in the Appendix (available at www.aaojournal.org). The dose,1081
Table 1. Dose, Volume, and Concentration of Study Drug
Study Drug and
Dose, mg
Volume
Delivered, ml Concentration, mg/ml
RTH258, 0.5 0.05 10
RTH258, 3.0 0.05 60
RTH258, 4.5 0.075 60
RTH258, 6.0 0.10 60
Ranibizumab, 0.5 0.05 10
Ophthalmology Volume 123, Number 5, May 2016injection volume, and concentration for the RTH258 0.5-, 3.0-, 4.5-,
and 6.0-mg doses and the ranibizumab 0.5-mg dose are shown in
Table 1.
At screening, all patients underwent best-corrected visual
acuity (BCVA) assessments for both eyes, bilateral ophthalmic
examinations, color fundus photography, ﬂuorescein angiog-
raphy, and measurements of central subﬁeld thickness (CSFT) by
SD OCT. The CSFT was measured for both eyes at screening and
for the study eye at all post-screening study visits using an SD
OCT instrument (SPECTRALIS; Heidelberg Engineering, Hei-
delberg, Germany). Retinal images obtained at screening were
sent to a central reading center for the determination of patient
eligibility on the basis of the lesion attributes speciﬁed in the
inclusion criteria. Eligible and randomized patients received a
single intravitreal injection of the study drug. All patients were
monitored post-injection for optic nerve head perfusion and
health of the eye until the central retinal artery was adequately
perfused. Intraocular pressure in the study eye was monitored
until the pressure was <30 mmHg and considered stable by the
study investigator. Patients were monitored for adverse events
(AEs) and instructed to seek immediate care from an ophthal-
mologist if the study eye became red, sensitive to light, or
painful, or if there was a change in vision.N=194
RTH258 0.5 mg
RTH258 3.0 mg
RTH258 6.0 mg
Evaluable, n=10
Evaluable, n=35
Evaluable, n=40
Evaluable, n=48
Randomized*/Intent to Treat†
RTH258 4.5 mg
 Ranibizumab 0.5 mg Evaluable, n=61
Figure 1. Patient disposition. ITT ¼ intent-to-treat.
1082Patients
Treatment-naive patients, aged 50 years, presenting with primary
subfoveal choroidal neovascularization secondary to AMD,
including predominantly classic, minimally classic, or occult le-
sions at screening, were eligible to participate in the study. The
study enrolled patients at 51 sites in the United States, Europe,
Israel, and Australia. The study was conducted from October 2010
to March 2013. Details concerning the inclusion and exclusion
criteria are provided in Table 2 (available at www.aaojournal.org).
Outcomes
The primary efﬁcacy end point was the change from baseline to
month 1 in CSFT as measured by SD OCT. The secondary efﬁcacy
end point was the duration of treatment effect measured by the time
from initial treatment to the receipt of post-baseline therapy (PBT)
as decided by the study investigator guided by protocol-speciﬁed
criteria. Additional supportive analyses were conducted for the
change from baseline in CSFT and BCVA at all time points in the
study. Visual acuity was assessed using the Electronic Early
Treatment Diabetic Retinopathy Study chart on an electronic tester
at 3 m and was calculated as the number of letters read correctly
plus 5 letters for each logarithm of the minimum angle of resolu-
tion line above the upper logarithm of the minimum angle of res-
olution level through 20/800.
Post-baseline therapy for exudative AMD was recommended on
the basis of the following criteria: (1) beginning on day 14 if, in the
opinion of the investigator, there was a decrease in the change from
baseline in CSFT of <50 mm at any visit, a new intraocular
hemorrhage deemed clinically signiﬁcant, or vision loss of 7
letters of BCVA associated with an accumulation of retinal ﬂuid
compared with baseline; (2) beginning with month 1 if, in the
opinion of the investigator, there was a 340-mm CSFT on SD
OCT (based on the value speciﬁed for initial treatment in theSafety‡
N=194
Evaluable, n=11
Evaluable, n=31
Evaluable, n=44
Evaluable, n=47
Evaluable, n=61
*Six RTH258 patients were 
incorrectly dosed during the 
study as follows:
• 4 randomized to 3.0 mg 
but received 6.0 mg
• 1 randomized to 4.5 mg 
but received 3.0 mg
• 1 randomized to 3.0 mg 
but received 0.5 mg
† The ITT set included all 
patients for their 
randomized dose
‡ The safety set included
all patients at their
actual dose
Table 3. Patient Demographics and Baseline Characteristics (Safety-Analysis Set)
RTH258 0.5 mg
(n [ 11)
RTH258 3.0 mg
(n [ 31)
RTH258 4.5 mg
(n [ 47)
RTH258 6.0 mg
(n [ 44)
Ranibizumab 0.5
mg (n [ 61)
Overall
(N [ 194)
Mean (SD) age 75.7 (6.5) 78.4 (8.3) 75.3 (7.7) 74.8 (9.8) 77.8 (8.1) 76.5 (8.4)
Sex, n (%)
Male 5 (45.5) 19 (61.3) 21 (44.7) 15 (34.1) 28 (45.9) 88 (45.4)
Female 6 (54.5) 12 (38.7) 26 (55.3) 29 (65.9) 33 (54.1) 106 (54.6)
Race, n (%)
White 11 (100.0) 31 (100.0) 47 (100.0) 43 (97.7) 61 (100.0) 193 (99.5)
American Indian or
Alaska Native
0 (0.0) 0 (0.0) 0 (0.0) 1 (2.3) 0 (0.0) 1 (0.5)
Mean (SD) days since
diagnosis
29.6 (20.6) 18.9 (15.7) 24.1 (32.3) 21.0 (14.8) 24.0 (19.9) 22.8 (22.1)
Mean (SD) BCVA letters 63.6 (8.6) 57.9 (12.6) 56.8 (10.8) 54.9 (10.8) 56.6 (11.3) 56.9 (11.2)
Mean (SD) CSFT, mm 526.3 (102.9) 530.3 (177.6) 534.6 (166.1) 498.1 (115.8) 509.5 (121.9) 517.3 (140.9)
BCVA ¼ best-corrected visual acuity; CSFT ¼ central subﬁeld thickness; SD ¼ standard deviation.
Holz et al  RTH258 for the Treatment of Neovascular AMDinclusion criteria), a vision loss of 7 letters of BCVA associated
with an accumulation of retinal ﬂuid compared with the previous
visit, or a new intraocular hemorrhage deemed clinically signiﬁ-
cant. After day 14 and month 1, the need for PBT was evaluated at
1.5, 2.0, 2.5, 3, 4, 5, and 6 months using the listed criteria. The
choice of PBT was at the discretion of the investigator on a patient-
by-patient basis in accord with the respective approved product
information, as was therapy for the nonstudy eye throughout the
study.
RTH258 serum concentration at each collection time point was
measured using a validated enzyme-linked immunosorbent assayMont
M
ea
n 
CS
FT
 C
ha
ng
e 
± 
SE
, μ
m
Median Time to Post-Baseline Therapy
0.0 0.5 1.0 1.5 2.0 2.5 3.0
0
–50
–100
–150
–200
–250
RTH258 0.5 mg
RTH258 3.0 mg
RTH258 4.5 mg
RTH258 6.0 mg
Ranibizumab 0.5 mg
0.0
6.5
0.0
2.3
3.3
9.1
6.5
8.5
9.1
4.9
36.4
16.1
27.7
29.5
27.9
72.7
29.0
36.2
34.1
57.4
81.8
48.4
51.1
45.5
70.5
90.9
61.3
70.2
59.1
75.4
Figure 2. Central subﬁeld thickness (CSFT) mean change from baseline to mo
baseline therapy (PBT) and reﬂect the last value carried forward for each patie
forward (LVCF) patient data are shown in the chart under the graph.method. These data were analyzed using a noncompartmental
pharmacokinetic method to calculate maximum concentration, area
under the curve (AUC) from time 0 to last measurable time point,
AUC from time 0 extrapolated to inﬁnity, and half-life for each
patient.
The primary safety evaluation in this study was the incidence of
AEs occurring in the study eye within 7 days of the intravitreal
injection. In addition, anti-RTH258 serum antibodies were deter-
mined, and the following safety parameters were assessed: ocular
signs, posterior segment, abnormalities, evaluation of retinal
hemorrhage/detachment, evaluation of vitreous hemorrhagehs
RTH258 0.5 mg
RTH258 3.0 mg
RTH258 4.5 mg
RTH258 6.0 mg
Ranibizumab 0.5 mg
3.5 4.0 4.5 5.0 5.5 6.0
---
---
---
---
---
90.9
67.7
72.3
65.9
83.6
90.9
83.9
78.7
75.0
85.2
---
---
---
---
---
---
---
---
---
---
100.0
93.5
85.1
84.1
88.5
n=11
n=31
n=47
n=44
n=61
nth 6; safety-analysis set. Data were censored after administration of post-
nt after administration of study drug. The percentage of last value carried
1083
0 10 20 30 40 50 60 70 80 90 100 110 120 130 140 150 160 170 180
0
10
20
30
40
50
60
70
80
90
100
Time to Post-Baseline Therapy (Days)
Pr
ob
ab
ili
ty
 o
f R
ec
ei
vi
ng
 S
ta
nd
ar
d 
of
 C
ar
e 
(%
) RTH258 0.5 mg (n=10)
Ranibizumab 0.5 mg (n=61)
50% Receive Post-Baseline Therapy
Test Chi-Square DF p-value 
Log-Rank 1.7348 1 0.1878 
Wilcoxon 1.2568 1 0.2623 
0 10 20 30 40 50 60 70 80 90 100 110 120 130 140 150 160 170 180
0
10
20
30
40
50
60
70
80
90
100
Time to Post-Baseline Therapy (Days)
Pr
ob
ab
ili
ty
 o
f R
ec
ei
vi
ng
 S
ta
nd
ar
d 
of
 C
ar
e 
(%
) RTH258 4.5 mg (n=48)
Ranibizumab 0.5 mg (n=61)
15 days 50% Receive Post-Baseline Therapy
Test Chi-Square DF p-value 
Log-Rank 1.9100 1 0.1670 
Wilcoxon 1.7934 1 0.1805 
0 10 20 30 40 50 60 70 80 90 100 110 120 130 140 150 160 170 180
0
10
20
30
40
50
60
70
80
90
100
Time to Post-Baseline Therapy (Days)
Pr
ob
ab
ili
ty
 o
f R
ec
ei
vi
ng
 S
ta
nd
ar
d 
of
 C
ar
e 
(%
) RTH258 3.0 mg (n=35)
Ranibizumab 0.5 mg (n=61)
30 days
50% Receive Post-Baseline Therapy
Test Chi-Square DF p-value 
Log-Rank 1.1451 1 0.2846 
Wilcoxon 4.3300 1 0.0374 
0 10 20 30 40 50 60 70 80 90 100 110 120 130 140 150 160 170 180
0
10
20
30
40
50
60
70
80
90
100
Time to Post-Baseline Therapy (Days)
Pr
ob
ab
ili
ty
 o
f R
ec
ei
vi
ng
 S
ta
nd
ar
d 
of
 C
ar
e 
(%
) RTH258 6.0 mg (n=40)
Ranibizumab 0.5 mg (n=61)
30 days 50% Receive Post-Baseline Therapy
Test Chi-Square DF p-value 
Log-Rank 4.1668 1 0.0412 
Wilcoxon 4.3961 1 0.0360 
Figure 3. KaplaneMeier curves; time to receiving post-baseline therapy (PBT); safety-analysis set. DF ¼ degrees of freedom.
Ophthalmology Volume 123, Number 5, May 2016density and vitreous cells, intraocular pressure, eyelid/pupil
responsiveness, postinjection evaluation of the study eye, physical
examination, vital signs, clinical laboratory tests, and all other AEs.
Statistical Analyses
The efﬁcacy analysis was initially to be conducted using the intent-
to-treat (ITT) patients. The ITT set included all patients who were
randomized, received study drug, and completed 1 scheduled on-
therapy study visit. The safety set included all patients who
received study drug with treatment group allocation according to
the actual treatment received. Because 6 patients receiving
RTH258 did not receive the correct treatment doses when ran-
domized on day 0, an ad hoc efﬁcacy analysis was performed on
the basis of actual treatment received (i.e., the safety analysis set).
There was no indication that the misdosed patients in the RTH258
treatment arms constituted a source of a systematic bias. For this
phase 1/2 proof-of-concept study, an as-treated efﬁcacy analysis
was conducted to allow for the most relevant evaluation of efﬁ-
cacy. Sensitivity analysis of efﬁcacy comparing the outcome of the
analysis based on the ITT set and safety set led to the same con-
clusions. Other amendments to the study protocol are reported in
the Appendix (available at www.aaojournal.org).
To eliminate a potential positive effect of PBT on the time-
course of CSFT and BCVA, the data presented are based
on censoring of assessments after receipt of PBT and using the1084last-observation-carried-forward method to impute censored and
missing data. Data after administration of PBT were censored and
artiﬁcially rendered “missing” to eliminate any effects of PBT. We
will refer to this methodology as the last value (on study treatment)
carried forward.
Noninferiority hypothesis testing relating the primary end point
change from baseline to month 1 in CSFT was prespeciﬁed for
RTH258 4.5 and 6.0 mg in comparison with ranibizumab. Two-
sided 90% conﬁdence intervals (CIs) for the treatment differ-
ences were used to assess these hypotheses, with noninferiority
being concluded if the lower limit was greater than e40 mm (the
noninferiority margin, derived from historical data). Corresponding
CIs were derived from pairwise analysis of variance models with
treatment and baseline CSFT category (<400, 400e600, and>600 mm)
as factors in the model. No adjustment was planned for multiple
testing. Details regarding the determination of sample sizes for
the study are available in the Appendix (available at
www.aaojournal.org).
The KaplaneMeier method was used to assess the distribution
of time from the initial study drug injection to the receipt of PBT.
Treatment differences regarding the supportive end point BCVA
were assessed using 90% CIs derived from an analysis of variance
model with treatment and baseline BCVA category (<55 and 55
letters) as factors.
The independent safety review at each dose escalation approved
ascension to the next higher dose up to the MFD and preserved
Months
RTH258 0.5 mg
RTH258 3.0 mg
RTH258 4.5 mg
RTH258 6.0 mg
Ranibizumab 0.5 mg
Median Time to Post-Baseline Therapy
0.0 0.5 1.0 1.5 2.0 2.5 3.0 3.5 4.0 4.5 5.0 5.5 6.0
15
10
5
0
RTH258 0.5 mg
RTH258 3.0 mg
RTH258 4.5 mg
RTH258 6.0 mg
Ranibizumab 0.5 mg
0.0
6.5
0.0
2.3
3.3
9.1
6.5
8.5
9.1
4.9
36.4
16.1
27.7
29.5
27.9
72.7
29.0
36.2
34.1
57.4
81.8
48.4
51.1
45.5
70.5
90.9
61.3
70.2
59.1
75.4
---
---
---
---
---
90.9
67.7
72.3
65.9
83.6
90.9
83.9
78.7
75.0
85.2
---
---
---
---
---
---
---
---
---
---
100.0
93.5
85.1
84.1
88.5
n=11
n=31
n=47
n=44
n=61
Figure 4. Best-corrected visual acuity (BCVA) mean change from baseline to month 6; safety-analysis set. Data were censored after administration of post-
baseline therapy (PBT) and reﬂect the last value carried forward for each patient after administration of study drug. The percentage of last value carried
forward patient data are shown in the chart under the graph. ETDRS ¼ Early Treatment Diabetic Retinopathy Study.
Holz et al  RTH258 for the Treatment of Neovascular AMDmasking for the study investigators and study coordinators for all
patients during the dose escalation phase of the study. Therefore,
patients from both phases of the study were pooled together for the
efﬁcacy and safety assessments.Results
Patients
In total, 194 patients were randomized and received intravitreal
injections of the study drug. Figure 1 shows the patient disposition
in the study. All patients randomized to the RTH258 0.5- and 3.0-
mg doses completed the study, and 1 patient each in the RTH258
4.5-mg, RTH258 6.0-mg, and ranibizumab 0.5-mg groups dis-
continued (each because of an AE not related to study treatment)
before study completion. All 194 patients were included in the ITT
and safety analysis sets. During the study, 6 patients receiving
RTH258 were incorrectly dosed: Four patients randomized to
receive 3.0 mg received 6.0 mg, 1 patient randomized to receive
4.5 mg received 3.0 mg, and 1 patient randomized to receive 3.0
mg received 0.5 mg.
The majority of the 194 patients were white (99.5%) and aged
65 years (91.2%), with a mean (standard deviation [SD]) age of
76.5 (8.4) years. For all patients, the mean (SD) time from the
diagnosis of neovascular AMD in the study eye to randomization
was 22.8 (22.1) days, and the BCVA in letters read at baseline was
56.9 (11.2). The mean (SD) CSFT at baseline was 517.3 (140.9)
mm. Of the 194 patients, 156 (80.4%) had a unilateral diagnosis at
baseline. The patient demographic characteristics in the safety set
are summarized in Table 3; there were no clinically meaningful
differences between the treatment groups.Efﬁcacy
For the as-treated patients in the safety-analysis set, the least
squares mean difference in the mean change from baseline to
month 1 in CSFT revealed a 21.09 (90% CI, 8.83 to 51.00) mm
larger reduction for the RTH258 4.5-mg group compared with the
ranibizumab 0.5-mg group. The least squares mean difference in
the mean change from baseline to month 1 in CSFT was 10.34
(90% CI, 18.18 to 38.86) mm in favor of the RTH258 6.0-mg
group versus the ranibizumab 0.5-mg group. In both compari-
sons, the lower bound of the 90% CI was greater than the non-
inferiority margin of 40 mm, demonstrating the noninferiority of
RTH258 to ranibizumab in the mean change from baseline in
CSFT to month 1. The results obtained for the safety-analysis set
were consistent with those obtained for the ITT set.
The time course of mean CSFT change from baseline (Fig 2)
showed a numeric advantage for the RTH258 3.0-, 4.5-, and 6.0-
mg groups when compared with the ranibizumab 0.5-mg group
from day 7 to month 2.5. The 3.0-, 4.5-, and 6.0-mg doses of
RTH258 had similar proﬁles up to month 1, after which there was a
tendency for CSFT to increase in the RTH258 3.0- and 4.5-mg
groups, and the ranibizumab 0.5-mg group. In contrast, CSFT
observed in the RTH258 6.0-mg group remained stable between
month 1 and month 1.5, with an increase occurring toward month
2. In total, 9 patients had received PBT by day 14, 1 patient in the
0.5-mg RTH258 group, 3 patients in the 4.5-mg RTH258 group, 2
patients in the 6.0-mg group, and 3 patients in the ranibizumab
group.
On the basis of the time to PBT, a trend toward a longer
duration of effect was observed in each RTH258 group relative to
the ranibizumab 0.5-mg group, except in the RTH258 0.5-mg
group. At month 1, 4 of 31 patients in the RTH258 3.0-mg1085
Table 4. Descriptive Statistics for Pharmacokinetic Parameters by
Treatment
Pharmacokinetic Parameter n Mean (SD)
Harmonic
Mean (SD)
Overall
tlast, d 110 12.7 (5.36)
t1/2, d 68 6.2 (3.74) 5.01 (2.97)
RTH258, mg
0.5
Cmax, ng/ml 9 1.50 (0.85)
tlast, d 4 9.3 (3.20)
AUC0-last, ng*d/ml 4 12.19 (4.86)
AUC0-inf, ng*d/ml 1 25.9 (—)*
t1/2, d 1 11.0 (—)* 11.0 (—)*
3.0
Cmax, ng/ml 30 5.61 (6.22)
tlast, d 24 11.0 (3.43)
AUC0-last, ng*d/ml 24 34.33 (28.74)
AUC0-inf, ng*d/ml 13 63.4 (33.6)
t1/2, d 13 7.1 (6.24) 4.86 (4.30)
4.5
Cmax, ng/ml 45 5.71 (2.59)
tlast, d 41 12.6 (4.76)
AUC0-last, ng*d/ml 41 41.46 (20.29)
AUC0-inf, ng*d/ml 26 62.7 (24.7)
t1/2, d 26 5.7 (2.70) 4.89 (2.28)
6.0
Cmax, ng/ml 43 8.53 (7.27)
tlast, d 41 14.3 (6.51)
AUC0-last, ng*d/ml 41 64.18 (51.41)
AUC0-inf, ng*d/ml 28 83.2 (52.6)
t1/2, d 28 6.2 (3.01) 5.10 (2.78)
AUC0-inf ¼ area under the curve from time 0 extrapolated to inﬁnity;
AUC0-last ¼ area under the curve from time 0 to last measurable time
point; Cmax ¼ maximum concentration; SD ¼ standard deviation; t1/2 ¼
half-life; tlast ¼ time to last measureable time point.
*SD not calculable because n ¼ 1.
Ophthalmology Volume 123, Number 5, May 2016group, 12 of 47 patients in the RTH258 4.5-mg group, 11 of 44
patients in the RTH258 6.0-mg group, and 17 of 61 patients in
the ranibizumab 0.5-mg group had received PBT. On the basis of
the KaplaneMeier analysis, the median times to receiving PBT
for patients in the RTH258 0.5-, 3.0-, 4.5-, and 6.0-mg groups
were 45, 75, 60, and 75 days, respectively, whereas the median
time was 45 days with ranibizumab. These differences between
the RTH258 treatment groups and the ranibizumab 0.5-mg group
(Fig 3) were assessed using the Wilcoxon test (P ¼ 0.26, 0.04,
0.18, and 0.04 for the 0.5-, 3.0-, 4.5-, and 6.0-mg groups,
respectively).
The mean changes from baseline in BCVA observed in the
RTH258 6.0-mg group were consistently larger than those
observed in the ranibizumab 0.5-mg group at all post-baseline
study visits (Fig 4). The mean and the corresponding 90% CI
for the BCVA change from baseline suggested potential
advantages for RTH258 6.0 mg, speciﬁcally at months 1
(1.99 [90% CI, 4.87 to 0.89] letters), 1.5 (4.05 [90%
CI, 7.10 to 1.00] letters), and 2 (2.08 [90% CI, 5.13 to
0.96] letters).
The time course of mean BCVA change from baseline (Fig 4)
observed in the RTH258 0.5-, 3.0-, and 4.5-mg groups was
generally consistent with the time course observed in the ranibi-
zumab 0.5-mg group. Although the BCVA tended to worsen in the
ranibizumab 0.5-mg group after month 1, it further improved1086between months 1 and 1.5 in the RTH258 3.0-, 4.5-, and 6.0-mg
groups.
Pharmacokinetics of RTH258
Serum RTH258 levels were low but quantiﬁable in most patients
after a single intravitreal injection of RTH258. The maximum
concentration and AUC values increased with each dose, and the
peak serum RTH258 concentration was observed in the ﬁrst time
point after dosing (1 day); after that, the RTH258 concentration
demonstrated a mono-exponential decay, with an overall harmonic
mean (SD) half-life of 5.10 (2.78) days. Pharmacokinetic param-
eters by each RTH258 dose are summarized in Table 4.
Safety
The safety population comprised 194 patients who were exposed to
the study drug. Treatment-emergent AEs are summarized in
Table 5. The most frequent AEs related to the administration
procedure reported among patients treated with RTH258 were
conjunctival hemorrhage, eye pain, and conjunctival hyperemia;
the majority of these events were mild in intensity and resolved
within a few days without the need for treatment. The features of
these events were not uncharacteristic of those observed for
intravitreal injections in general, and no cases of endophthalmitis
were reported. No patient exposed to RTH258 discontinued
study participation because of a treatment-emergent AE. Seven-
teen patients experienced serious AEs: 7 of 61 patients in the
ranibizumab and 4 of 31, 3 of 47, and 3 of 44 patients in the
RTH258 3.0-mg, 4.5-mg, and 6.0-mg groups, respectively. None
of the reported serious AEs were considered related to treatment.
In Table 5, hypertension AEs are reported only in patients who
were randomized to RTH258. These AEs were all reported on a
change in concomitant medication and not related to measured
blood pressure at scheduled or unscheduled visits. In 6 of the 8
patients, the change in concomitant medication occurred 40 to
140 days post-RTH258 administration and after receipt of PBT
in 3 of these 6 patients. Three similar instances of concomitant
blood pressureelowering medication changes in hypertensive pa-
tients randomized to ranibizumab were reported as disease change
rather than AE, and a single instance of an AE “blood pressure
systolic increased” in a fourth patient randomized to ranibizumab is
not included in Table 5.
Discussion
In this phase 1/2 proof-of-concept study, RTH258 met the
primary objective of demonstrating noninferiority (margin:
40 mm, 1-sided alpha 0.05) to ranibizumab 0.5 mg in the
change in CSFT from baseline to month 1 after a single
intravitreal injection of the RTH258 4.5- or 6.0-mg dose.
The mean change in CSFT over time showed a numerically
better outcome for RTH258 3.0, 4.5, and 6.0 mg when
compared with ranibizumab 0.5 mg from day 7 to month
2.5. After a single intravitreal injection, RTH258 3.0, 4.5,
and 6.0 mg led to a greater median time to receiving PBT
(75, 60, and 75 days, respectively) when compared with
ranibizumab 0.5 mg (45 days), suggesting a more durable
response for the majority of patients. Likewise, the time
course of the change in BCVA showed improvement be-
tween months 1 and 1.5 with RTH258 at 3.0, 4.5, and 6.0
mg, whereas the change in BCVA tended to worsen in the
ranibizumab group after month 1. The censoring of assess-
ments after receipt of PBT and using the last value carried
Table 5. Summary of Treatment-Emergent Adverse Events (Safety-Analysis Set)
Patients with AE, n (%)
RTH258 0.5 mg
(n [ 11)
RTH258 3.0 mg
(n [ 31)
RTH258 4.5 mg
(n [ 47)
RTH258 6.0 mg
(n [ 44)
Ranibizumab 0.5 mg
(n [ 61)
Serious AEs 0 (0.0) 4 (12.9) 3 (6.4) 3 (6.8) 7 (11.5)
Treatment-related 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Related to injection procedure 0 (0.0) 0 (0.0) 0 (0.0) 1 (2.3) 0 (0.0)
Not related to treatment 0 (0.0) 4 (12.9) 3 (6.4) 2 (4.5) 7 (11.5)
Most frequent treatment-emergent AEs; occurring in 3 patients in any treatment group
Conjunctival hemorrhage 0 (0.0) 3 (9.7) 3 (6.4) 8 (18.2) 2 (3.3)
Nasopharyngitis 1 (9.1) 0 (0.0) 3 (6.4) 3 (6.8) 2 (3.3)
Retinal hemorrhage 0 (0.0) 1 (3.2) 2 (4.3) 1 (2.3) 4 (6.6)
Visual acuity reduced 0 (0.0) 2 (6.5) 1 (2.1) 2 (4.5) 3 (4.9)
Hypertension 0 (0.0) 1 (3.2) 5 (10.6) 2 (4.5) 0 (0.0)
Urinary tract infection 0 (0.0) 4 (12.9) 1 (2.1) 2 (4.5) 0 (0.0)
Eye pain 0 (0.0) 0 (0.0) 4 (8.5) 1 (2.3) 1 (1.6)
Bronchitis 0 (0.0) 0 (0.0) 3 (6.4) 0 (0.0) 3 (4.9)
Pneumonia 0 (0.0) 1 (3.2) 0 (0.0) 0 (0.0) 3 (4.9)
Back pain 0 (0.0) 0 (0.0) 3 (6.4) 0 (0.0) 1 (1.6)
Patients with 1 treatment-emergent AE related to study drug
Iritis 0 (0.0) 0 (0.0) 1 (2.1) 1 (2.3) 0 (0.0)
Iridocyclitis 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (1.6)
Maculopathy 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (1.6)
Vitritis 0 (0.0) 0 (0.0) 1 (2.1) 0 (0.0) 0 (0.0)
Patients with 1 treatment-emergent AE related to the administration procedure
Conjunctival hemorrhage 0 (0.0) 3 (9.7) 2 (4.3) 6 (13.6) 1 (1.6)
Eye pain 0 (0.0) 0 (0.0) 2 (4.3) 1 (2.3) 0 (0.0)
Conjunctival hyperemia 0 (0.0) 1 (3.2) 0 (0.0) 0 (0.0) 1 (1.6)
Choroiditis 0 (0.0) 0 (0.0) 1 (2.1) 0 (0.0) 0 (0.0)
Corneal disorder 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (1.6)
Dry eye 0 (0.0) 1 (3.2) 0 (0.0) 0 (0.0) 0 (0.0)
Eye irritation 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (1.6)
Foreign body sensation in eyes 0 (0.0) 0 (0.0) 0 (0.0) 1 (2.3) 0 (0.0)
Visual acuity reduced 0 (0.0) 0 (0.0) 0 (0.0) 1 (2.3) 0 (0.0)
Vitreous ﬂoaters 0 (0.0) 0 (0.0) 1 (2.1) 0 (0.0) 0 (0.0)
AE ¼ adverse event.
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designed to eliminate a potential positive effect of PBT on
the time course of CSFT and BCVA.
The safety proﬁle of RTH258 in this single-dose study
was consistent with the known safety proﬁle of intravitreally
injected anti-VEGF agents and did not show any unexpected
ﬁndings. No patient in the RTH258 dose groups dis-
continued the study because of a treatment-emergent AE,
and there were no reports of endophthalmitis. In the phase 2
OSPREY study, 6 mg of RTH258 was dosed over 1 year
and well tolerated.17
Visual acuity (BCVA) remains an important primary
outcome assessment in clinical trials of treatments for neo-
vascular AMD, and at 1 year the outcome was the primary
end point in the Anti-VEGF Antibody for the Treatment of
Predominantly Classic Choroidal Neovascularization in
AMD (ANCHOR),9 Minimally Classic/Occult Trial of the
Anti-VEGF Antibody Ranibizumab in the Treatment of
Neovascular AMD (MARINA),10 and VEGF Trap-Eye:
Investigation of Efﬁcacy and Safety in Wet AMD 1 and 2
(VIEW 1 and 2)18 pivotal trials, validating visual acuity as a
viable long-term study assessment.19,20 In addition, current
SD OCT systems provide greatly improved images of the
intraretinal cysts, intraretinal ﬂuid, subretinal ﬂuid, and
subretinal pigment epithelium ﬂuid compared with time-domain optical coherence tomography.21 In this proof-of-
concept study, with a primary end point at month 1,
treatment consisting of a single intravitreal injection, and
small sample sizes over multiple dose groups, CSFT was
chosen as a noninvasive and objective assessment21 of
anatomic response to treatment that is more sensitive than
BCVA at the 1-month time point. The EXCITE study
compared monthly with quarterly ranibizumab treatment
regimens over the course of 1 year using both BCVA and
retinal morphology assessed by optical coherence tomog-
raphy, which demonstrated a stronger effect size for optical
coherence tomography compared with BCVA at 1 month.22
Although improvement in visual acuity was noted in this
study, longerterm, multidose studies will be needed to
objectively compare RTH258 with other anti-VEGF treat-
ments in terms of changes in BCVA. One such trial
(NCT01796964) currently is being analyzed.
Compared with ranibizumab 0.5 mg, the median time to
PBT for the RTH258 3.0-, 4.5-, and 6.0-mg doses were
observed to be longer by approximately 15 to 30 days. As a
surrogate estimate of durability, this result suggests that the
smaller (26 kDa) RTH258, at a higher concentration of
active drug (6.0 mg; i.e., a 22-fold molar amount) with a
high binding afﬁnity for VEGF with a KD of 104 pM
compared with a KD of 96 pM for aﬂibercept, <171 pM for1087
Ophthalmology Volume 123, Number 5, May 2016ranibizumab, and 3300 pM for bevacizumab,15,16 may have
accounted for an increase in the durability of the response to
treatment. Results from this study also indicate the safety
and tolerability of the high RTH258 6.0-mg dose, suggest-
ing that it has potential to show clinical efﬁcacy at dosing
intervals longer than 1 month.
Study Limitations
A limitation of the study relates to the varied volumes
administered for each of the different RTH258 study doses.
Although a relatively small overall study population, the
sample size was adequate to assess noninferiority of
RTH258 versus ranibizumab on the basis of an anatomic
response to treatment 1 month after injection. Another
limitation concerns the revised efﬁcacy analysis using the
as-treated patients (safety set) rather than the ITT patient set
as originally planned in the study protocol. However,
sensitivity analysis of efﬁcacy comparing the outcome of the
analysis based on the ITT set and safety set led to the same
conclusions.
In conclusion, this ﬁrst-in-human, proof-of-concept study
of RTH258 compared with ranibizumab for the treatment of
wet AMD demonstrated noninferiority (margin: 40 mm, 1-
sided alpha 0.05) in the 1-month change in CSFT at 4.5-
and 6.0-mg doses, with an observed increase of 30 days in
the median time to administering PBT for the 6.0-mg dose.
There were no unexpected safety concerns with RTH258 at
any dose level, and the results support the continued
development of RTH258 at the 6.0-mg dose for the treat-
ment of wet AMD. Full results of the phase 2 study
OSPREY17 will be reported soon, and phase 3 studies have
started enrolling patients (NCT02307682 and
NCT02434328).
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